MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions

Future Oncology 2015 December 3 [Epub ahead of print] [Link]

Karim S, Leighl N.

Abstract

New insights into the interaction between the immune system and the tumor microenvironment have led to the development of checkpoint inhibitors that target the PD-1/PD-L1 pathway. Pembrolizumab (MK-3475, lambrolizumab, Keytruda®) is a PD-1 inhibitor that has shown clinical activity in a variety of solid tumors and is currently approved for the second-line treatment of PD-L1-positive non-small-cell lung cancer and for unresectable/metastatic melanoma. This article will discuss the results of early-phase trials of pembrolizumab in thoracic malignancies as well as ongoing studies aimed to confirm clinical benefit.

Both comments and trackbacks are currently closed.